JP2019512020A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512020A5
JP2019512020A5 JP2018561191A JP2018561191A JP2019512020A5 JP 2019512020 A5 JP2019512020 A5 JP 2019512020A5 JP 2018561191 A JP2018561191 A JP 2018561191A JP 2018561191 A JP2018561191 A JP 2018561191A JP 2019512020 A5 JP2019512020 A5 JP 2019512020A5
Authority
JP
Japan
Prior art keywords
vaccine
days
use according
inhibitor
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2018561191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512020A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/017445 external-priority patent/WO2017139628A1/en
Publication of JP2019512020A publication Critical patent/JP2019512020A/ja
Publication of JP2019512020A5 publication Critical patent/JP2019512020A5/ja
Priority to JP2022064122A priority Critical patent/JP2022088665A/ja
Ceased legal-status Critical Current

Links

JP2018561191A 2016-02-12 2017-02-10 がんの治療 Ceased JP2019512020A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022064122A JP2022088665A (ja) 2016-02-12 2022-04-07 がんの治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662294349P 2016-02-12 2016-02-12
US62/294,349 2016-02-12
US201662404252P 2016-10-05 2016-10-05
US62/404,252 2016-10-05
PCT/US2017/017445 WO2017139628A1 (en) 2016-02-12 2017-02-10 Cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022064122A Division JP2022088665A (ja) 2016-02-12 2022-04-07 がんの治療

Publications (2)

Publication Number Publication Date
JP2019512020A JP2019512020A (ja) 2019-05-09
JP2019512020A5 true JP2019512020A5 (enExample) 2020-03-26

Family

ID=59088211

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018561191A Ceased JP2019512020A (ja) 2016-02-12 2017-02-10 がんの治療
JP2022064122A Pending JP2022088665A (ja) 2016-02-12 2022-04-07 がんの治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022064122A Pending JP2022088665A (ja) 2016-02-12 2022-04-07 がんの治療

Country Status (8)

Country Link
US (5) US11000578B2 (enExample)
EP (1) EP3413927A4 (enExample)
JP (2) JP2019512020A (enExample)
CN (1) CN108883203A (enExample)
AU (1) AU2017217940B2 (enExample)
CA (1) CA3013930C (enExample)
HK (1) HK1258319A1 (enExample)
WO (1) WO2017139628A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
AU2019327490A1 (en) * 2018-08-30 2021-03-25 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
WO2020097209A1 (en) * 2018-11-06 2020-05-14 Wisconsin Alumni Research Foundation Treating prostate cancer using a combination of a dna vaccine, pd-1 inhibitor and an ido inhibitor
CN109593135B (zh) * 2018-12-29 2021-01-15 百奥赛图江苏基因生物技术有限公司 抗人pd-l1单克隆抗体及其应用
AU2020218259A1 (en) * 2019-02-08 2021-09-02 Madison Vaccines Inc. Cancer therapy
CN110632292A (zh) * 2019-06-12 2019-12-31 江苏莱尔生物医药科技有限公司 一种检测pd-l1和cd8抗原的免疫荧光试剂盒及应用方法
WO2021108331A1 (en) * 2019-11-26 2021-06-03 The Regents Of The University Of California Combination therapy for head and neck cancer
CN111141906A (zh) * 2020-01-06 2020-05-12 中南大学湘雅医院 一种小细胞肺癌患者外周血循环肿瘤细胞及pd-l1的检测试剂盒
EP4175664A2 (en) * 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2023118360A1 (en) 2021-12-23 2023-06-29 Universiteit Maastricht Immunoprotective type implantable cell delivery device

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
AU7994200A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US7179797B2 (en) 2002-09-27 2007-02-20 Wisconsin Alumni Research Foundation Methods and compositions for treating prostate cancer using DNA vaccines
US20070232558A1 (en) 2006-03-31 2007-10-04 Mcneel Douglas G Methods and compositions for treating prostate cancer using dna vaccines directed to cancer testis antigen
US7910565B2 (en) 2006-09-01 2011-03-22 Wisconsin Alumni Research Foundation Prostate cancer vaccine
WO2008085562A2 (en) 2006-09-20 2008-07-17 The Johns Hopkins University Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
US9060961B2 (en) 2006-11-09 2015-06-23 University Of Washington Molecules and methods for treatment and detection of cancer
WO2008103645A2 (en) 2007-02-19 2008-08-28 Wisconsin Alumni Research Foundation Prostate cancer and melanoma antigens
WO2009052328A1 (en) 2007-10-18 2009-04-23 Bn Immunotherapeutics Inc. Use of mva to treat prostate cancer
EP2419126B1 (en) 2009-04-17 2018-01-10 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
US20110301052A1 (en) 2010-04-16 2011-12-08 Mcneel Douglas G Diagnostic evaluation of antibody responses to commonly recognized prostate cancer-associated antigens
US8603485B2 (en) 2011-01-05 2013-12-10 Wisconsin Alumni Research Foundation Bystander immune suppression as a predictor for response to a vaccine
NZ701324A (en) * 2012-05-04 2016-09-30 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
EP4070818A3 (en) 2014-01-06 2023-01-11 The Trustees of the University of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
MX2017000857A (es) * 2014-07-18 2017-10-11 Advaxis Inc Combinación de un antagonista de la proteina de muerte programada (pd-1) y una vacuna basada en listeria para tratar el cáncer de próstata.
JP2017535599A (ja) 2014-11-07 2017-11-30 ウィスコンシン アラムニ リサーチ ファンデーション B細胞標的dnaワクチン
WO2016094639A1 (en) 2014-12-10 2016-06-16 Wisconsin Alumni Research Foundation Mini-intronic plasmid dna vaccines in combination with lag3 blockade
WO2017139755A1 (en) 2016-02-12 2017-08-17 Rekoske Brian T Cancer therapy

Similar Documents

Publication Publication Date Title
JP2019512020A5 (enExample)
Khosravi et al. Immunologic tumor microenvironment modulators for turning cold tumors hot
JP7712970B2 (ja) ホットスポットを利用した新生抗原の特定
Pandya et al. The future of cancer immunotherapy: DNA vaccines leading the way
Schirrmacher From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment
JP7480064B2 (ja) パンアレルモデルによる新生抗原の特定方法
Chen et al. A neoantigen-based peptide vaccine for patients with advanced pancreatic cancer refractory to standard treatment
Zhang et al. Personalized cancer vaccines: Targeting the cancer mutanome
JP2021176866A (ja) 共通ネオ抗原
Zhu et al. Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?
JP2020169177A (ja) ネオエピトープワクチン組成物及びその使用方法
JP2017524337A5 (enExample)
Medler et al. Defining immunogenic and radioimmunogenic tumors
CN104853765A (zh) 肿瘤特异性t细胞受体
JP2018509163A5 (enExample)
TWI893039B (zh) 透過循環腫瘤dna分析之分子疾病評估之方法及系統
Liu et al. Advancements and challenges in peptide-based cancer vaccination: a multidisciplinary perspective
TW202146665A (zh) 減少基因採樣中的統計偏差
Kyte et al. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination
Mishchenko et al. Glioma: bridging the tumor microenvironment, patient immune profiles and novel personalized immunotherapy
KR20210018321A (ko) 종양 특이적 신생항원 및 이를 사용하는 방법
Suckow Cancer vaccines: harnessing the potential of anti-tumor immunity
CN106243213A (zh) 一种肿瘤相关抗原XAGE‑1b短肽及应用
Li et al. Context-dependent T-BOX transcription factor family: from biology to targeted therapy
Murphy et al. Immunotherapy in upper GI malignancies